Do Supplements Prevent Gestational Diabetes? Evidence Review

Only two supplements reduced gestational diabetes incidence in the largest review—and neither has settled the question

Supplements have a much weaker record in gestational diabetes (GDM) than their marketing suggests. In a 2021 meta-analysis of 53 randomized controlled trials involving 9,443 pregnant women, only myo-inositol and vitamin D significantly reduced the incidence of GDM. Omega-3 fatty acids, magnesium, chromium, zinc, and selenium did not show a demonstrated benefit for GDM prevention or management in that review.

The results sound impressive at first. Myo-inositol was associated with a relative risk of 0.34 for developing GDM (95% confidence interval [CI], 0.20 to 0.58), or a 66% relative reduction, across four studies. Vitamin D had a relative risk of 0.64 (95% CI, 0.44 to 0.94), a 36% relative reduction, across five studies. Both estimates were statistically significant in the 2021 meta-analysis by Chan et al.

But relative risk is not absolute risk, and the review does not provide an absolute risk reduction for those findings. More important, four or five small trials cannot establish that a supplement will work broadly across countries, diets, baseline nutrient status, and clinical settings. The review itself described the overall evidence as inconclusive. That is the honest starting point.

Myo-inositol has the biggest signal—and the biggest generalizability problem

Myo-inositol is a naturally occurring carbohydrate involved in cellular signaling and insulin-related pathways. It has become the supplement most often promoted for GDM prevention because its pooled estimate looks unusually large. Yet that estimate rests on only four prevention trials, with much of the underlying research conducted in Iran and Italy.

Geography matters here. Iranian populations have a high prevalence of vitamin D deficiency, while Italian dietary patterns may include more inositol-rich Mediterranean foods. Those differences do not prove that the trials were wrong. They do mean that a result in a geographically clustered set of studies may not transfer cleanly to a pregnant person in the United States, Singapore, New Zealand, or elsewhere.

A newer 2026 umbrella meta-analysis of inositol reviewed prior meta-analyses of both myo-inositol and D-chiro-inositol, including dose comparisons for GDM prevention and treatment. An umbrella review can summarize a field well, but it cannot repair weaknesses shared by the original trials. If the trials are small, clustered, or vulnerable to bias, pooling them more elegantly does not turn them into a definitive answer.

A 2023 double-blind randomized trial also tested low-dose myo-inositol in overweight pregnant women, a group at higher risk of GDM. Its design strengthens confidence in its internal comparison, but one trial in an overweight subgroup cannot establish a recommendation for all pregnancies. The available summary does not provide the effect estimate, so it should not be used to inflate the larger prevention claim.

The large international trial did not confirm the premise

The most important counterweight is the NiPPeR trial. This multicenter, double-blind randomized controlled trial enrolled women in the United Kingdom, Singapore, and New Zealand before conception. It compared a combined formulation of myo-inositol, probiotics, and micronutrients with a control and found no improvement in gestational normoglycemia.

That result from Godfrey et al.'s 2021 NiPPeR trial does not isolate the effect of myo-inositol, because the intervention combined several ingredients. Still, it is a rigorous international test in diverse populations, and its null result makes a blanket prevention claim hard to defend.

A secondary NiPPeR analysis adds another wrinkle. Higher early-pregnancy plasma myo-inositol levels were associated with higher post-meal glucose later in pregnancy, according to Chan et al.'s 2024 analysis. This is an association, not proof that myo-inositol raises glucose. Plasma levels may reflect diet, metabolism, or other factors. But it does challenge the tidy story that more myo-inositol necessarily means better insulin sensitivity.

The 2023 Cochrane review provides the more conservative reading: the evidence for antenatal myo-inositol remains limited enough that certainty, rather than enthusiasm, should set the tone.

Vitamin D: correct deficiency, but do not treat it as a proven GDM drug

Vitamin D also met statistical significance in the 2021 meta-analysis, with a relative risk of 0.64 (95% CI, 0.44 to 0.94) across five trials. That is a real pooled signal, not a license for indiscriminate supplementation.

Baseline deficiency may explain part of the effect. A person with low vitamin D status could plausibly respond differently than someone who already has adequate levels. The available trials do not establish that routine vitamin D supplementation prevents GDM in vitamin-D-replete populations. Testing for and treating documented deficiency has a clearer clinical rationale than taking extra vitamin D specifically to prevent GDM.

No major obstetric guideline body cited here—including ACOG, SMFM, WHO, or NICE—recommends myo-inositol or vitamin D specifically for GDM prevention. Guidelines can lag behind emerging research, but they also reflect the gap between a favorable pooled estimate and evidence strong enough for population-wide care.

Probiotics improve metabolic markers in established GDM, not proven pregnancy outcomes

Probiotics occupy a different category. The evidence concerns women who already have GDM, not prevention in healthy pregnancies. Four independent evidence syntheses report improvements in fasting blood glucose, fasting insulin, HOMA-IR, and lipid measures after probiotic or synbiotic supplementation.

Mu et al.'s 2023 meta-analysis found improvements in fasting glucose, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and LDL cholesterol. A 2024 umbrella meta-analysis by Sun et al., a 2024 RCT meta-analysis by Lan et al., and a 2022 systematic review by Çetinkaya Özdemir et al. reached similar conclusions for metabolic outcomes.

Convergence across several meta-analyses is encouraging, but the endpoints remain surrogates. Lower fasting glucose or HOMA-IR can matter clinically, yet these analyses have not shown that probiotics reduce macrosomia, preeclampsia, cesarean delivery, neonatal hypoglycemia, or NICU admission. A better lab panel is not the same thing as a better birth outcome.

The biology is plausible but not settled. In a case-control study of 110 women with GDM and 220 healthy pregnant women, Chen et al. found differences in second-trimester gut microbiota that were associated with glycemic traits. That association does not show that adding a commercial probiotic will reliably shift a person's microbiome or change her pregnancy outcome. Microbiomes are not houseplants; adding one strain does not guarantee the garden rearranges itself.

Lifestyle remains the intervention with the clearest clinical footing

Structured dietary planning and exercise remain the evidence-based foundation for GDM prevention and management. A 2024 Bayesian network meta-analysis evaluated dietary and exercise interventions, while a 2025 network meta-analysis assessed dietary interventions for glycemic control and pregnancy outcomes in women with GDM. These approaches are also consistent with NICE-endorsed dietary management.

When medication is needed for established GDM, insulin remains first-line pharmacotherapy in the cited review context; metformin and sulfonylureas require caution because they cross the placenta. Supplements sit below lifestyle care and prescribed treatment, not alongside them as interchangeable options.

The practical verdict

Myo-inositol is promising but unproven as a general GDM-prevention strategy. Its 66% relative-risk reduction deserves attention, but so do the four-trial evidence base, the geographic clustering, the international null NiPPeR result, and the paradoxical plasma-level association. A person at high risk of GDM can discuss it with an obstetric clinician; self-prescribing it as universal prevention runs ahead of the evidence.

Vitamin D makes the most sense when it corrects documented deficiency, not when it is marketed as a stand-alone GDM shield. Probiotics have the most consistent supplement evidence for improving metabolic markers after GDM develops, but no proof yet that they improve the pregnancy outcomes patients care about most. For omega-3s, magnesium, chromium, zinc, and selenium, the evidence does not support taking them specifically for GDM.

Supplements may have a role in selected pregnancies, but diet, activity, glucose monitoring, and clinician-guided treatment remain the interventions with the strongest practical evidence.